CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents

Biochemical and Biophysical Research Communications

Volumn 300, Issue 4, 2003, Pages 853-861

  Bhagat, Lakshmi ^a   Zhu, Fu Gang ^a   Yu, Dong ^a   Tang, Jimmy ^a   Wang, Hui ^b   Kandimalla, Ekambar R ^a   Zhang, Ruiwen ^b   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

3 3 linked; Anti cancer; IFN ,IL 12; IL 6; Immunomodulatory; Oligonucleotides; Phosphorothioate; Th1 immune response

Indexed keywords

CPG HEXADEOXYRIBONUCLEOTIDE; CPG PENTADEOXYRIBONUCLEOTIDE; DEOXYRIBONUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 5; INTERLEUKIN 6; NUCLEOTIDE; OVOTRANSFERRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER TISSUE; CELL CULTURE; CELL LINE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA SEQUENCE; DRUG DESIGN; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; SPLENOMEGALY; STRESS; TH1 CELL; TH2 CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

MINK CELL FOCUS-FORMING VIRUS; MURINAE; MUS MUSCULUS;

EID: 0037462875     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)02943-1     Document Type: Article

References (45)

1. Tokunaga T., Yamamoto H., Shimada S., Abe H., Fukuda T., Fujisawa Y., Furutani Y., Yano O., Kataoka T., Sudo T., Makiguchi N., Suganuma T. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG.I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72:1984;955-962.
2. Messina J.P., Gilkeson G.S., Pisetsky D.S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 147:1991;1759-1764.
3. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
4. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M.D., Silverman G.J., Lotz M., Carson D.A., Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273:1996;352-354.
5. Yamamoto S., Kuramoto E., Shimada S., Tokunaga T. In vitro augmentation of natural killer cell activity and production of interferon-. α/β and - γ with deoxyribonucleic acid fraction from Mycobacterium bovis BCG Jpn. J. Cancer Res. 79:1988;866-873.
6. Halpern M.D., Kurlander R.J., Pisetsky D.S. Bacterial DNA induces murine interferon-. γ production by stimulation of interleukin-12 and tumor necrosis factor- α Cell Immunol. 167:1996;72-78.
7. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon-. γ Proc. Natl. Acad. Sci. USA. 93:1996;2879-2883.
8. Zhao Q., Temsamani J., Zhou R.Z., Agrawal S. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 7:1997;495-502.
9. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18:2000;927-974.
10. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:2002;709-760.
11. Agrawal S., Kandimalla E.R. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. 8:2002;114-121.
12. Yamamoto S., Yamamoto T., Kataoka T., Kuramoto E., Yano O., Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J. Immunol. 148:1992;4072-4076.
13. Tokunaga T., Yano O., Kuramoto E., Kimura Y., Yamamoto T., Kataoka T., Yamamoto S. Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol. Immunol. 36:1992;55-66.
14. Liang H., Nishioka Y., Reich C.F., Pisetsky D.S., Lipsky P.E. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J. Clin. Invest. 98:1996;1119-1129.
15. Hartmann G., Weeratna R.D., Ballas Z.K., Payette P., Blackwell S., Suparto I., Rasmussen W.L., Waldschmidt M., Sajuthi D., Purcell R.H., Davis H.L., Krieg A.M. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164:2000;1617-1624.
16. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A Toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
17. Zhao Q., Temsamani J., Iadarola P.L., Jiang Z., Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem. Pharmacol. 51:1996;173-182.
18. Kandimalla E.R., Yu D., Agrawal S. Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr. Opin. Mol. Ther. 4:2002;122-129.
19. Zhao Q., Yu D., Agrawal S. Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg. Med. Chem. Lett. 9:1999;3453-3458.
20. Zhao Q., Yu D., Agrawal S. Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorg. Med. Chem. Lett. 10:2000;1051-1054.
21. ′ -internucleotide linkages Nucleic Acids Res. 30:2002;1613-1619.
22. Yu D., Kandimalla E.R., Zhao Q., Cong Y., Agrawal S. Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg. Med. Chem. 9:2001;2803-2808.
23. Yu D., Kandimalla E.R., Zhao Q., Cong Y., Agrawal S. Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg. Med. Chem. Lett. 11:2001;2263-2267.
24. Yu D., Kandimalla E.R., Zhao Q., Bhagat L., Cong Y., Agrawal S. Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA. Bioorg. Med. Chem. 11:2003;459-464.
25. Yu D., Kandimalla E.R., Cong Y., Tang J., Tang J.-Y., Zhao Q., Agrawal S. Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences. J. Med. Chem. 45:2002;4540-4548.
26. Kandimalla E.R., Yu D., Zhao Q., Agrawal S. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg. Med. Chem. 9:2001;807-813.
27. ′ -end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity Bioorg. Med. Chem. Lett. 10:2000;2585-2588.
28. ′ -end of CpG DNA affects immunostimulatory activity Bioconj. Chem. 13:2002;966-974.
29. ′ -linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents Nucleic Acids Res. 30:2002;4460-4469.
30. Yu D., Zhu F.G., Bhagat L., Wang H., Kandimalla E.R., Zhang R., Agrawal S. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem. Biophys. Res. Commun. 297:2002;83-90.
31. Iyer R.P., Eagan W., Regan J.B., Beaucage S.L. 3H-1,2 benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates. J. Am. Chem. Soc. 112:1990;1253-1254.
32. Branda R.F., Moore A.L., Mathews L., McCormack J.J., Zon G. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem. Pharmacol. 45:1993;2037-2043.
33. Davila E., Velez M.G., Heppelmann C.J., Celis E. Creating space: an antigen-independent, Cpg-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. Blood. 100:2002;2537-2545.
34. Stacey K.J., Sweet M.J., Hume D.A. Macrophages ingest and are activated by bacterial DNA. J. Immunol. 157:1996;2116-2122.
35. Yi A.K., Krieg A.M. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J. Immunol. 161:1998;4493-4497.
36. Serebrisky D., Teper A.A., Huang C.K., Lee S.Y., Zhang T.F., Schofield B.H., Kattan M., Sampson H.A., Li X.M. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J. Immunol. 165:2000;5906-5912.
37. Kitagaki K., Jain V.V., Businga T.R., Hussain I., Kline J.N. Immunomodulatory effects of CpG oligodeoxynucleotides on established Th2 responses. Clin. Diagn. Lab. Immunol. 9:2002;1260-1269.
38. Warren T.L., Weiner G.J. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma. Semin Oncol. 29(1 Suppl. 2):2002;93-97.
39. Hafner M., Zawatzky R., Hirtreiter C., Buurman W.A., Echtenacher B., Hehlgans T., Mannel D.N. Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res. 61:2002;5523-5528.
40. Lewis E.J., Agrawal S., Bishop J., Chadwick J., Cristensen N.D., Cuthill S., Dunford P., Field A.K., Francis J., Gibson V., Greenham A.K., Kelly F., Kilkushie R., Kreider J.W., Mills J.S., Mulqueen M., Roberts N.A., Roberts P., Szymkowski D.E. Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus. Antiviral Res. 48:2000;187-196.
41. Masihi K.N. Fighting infection using immunomodulatory agents. Expert Opin. Biol. Ther. 1:2001;641-653.
42. O'Hagan D.T., MacKichan M.L., Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng. 18:2001;69-85.
43. Leitner W.W., Hammerl P., Thalhamer J. Nucleic acid for the treatment of cancer: genetic vaccines and DNA adjuvants. Curr. Pharm. Des. 7:2001;1641-1667.
44. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv. Immunol. 73:1999;329-368.
45. Agrawal S., Temsamani J., Tang J.Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA. 88:1991;7595-7599.